Daiichi Sankyo Co. Ltd., of Tokyo, said Swissmedic, the regulatory authority of Switzerland, approved Lixiana (edoxaban), an oral, once-daily selective factor Xa inhibitor, to prevent stroke and systemic embolism in adults with nonvalvular atrial fibrillation.